DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20181923

Ormeloxifene in the management of dysfunctional uterine bleeding

L. Thulasi Devi, Ravi Nimonkar

Abstract


Background: Dysfunctional Uterine Bleeding (DUB), is the commonest cause of Abnormal Uterine Bleeding (AUB). It causes morbidity, anaemia, and unnecessary hysterectomies in women of fertile age group. This study attempts to study efficacy of medical management especially Selective Estrogen Receptor Modulator (SERM) namely Ormeloxefine (ORM) (Sevista®) in Perimenopausal women. Ormeloxifene was marketed in India for contraception under brand names Centron, Saheli, Choice-7, Novex and Novex-DS. It’s a benzopyran derivative also known as Centchroman which causes asynchronousity between ovulation and menstrual cycles possibly because of both estrogenic and anti-estrogenic actions. It has been known to cause delay in ovulation in clinical trials; however, majority have been unaffected. It causes delay in proliferation of endometrium thereby causing asynchronous cycles. It also improves motility of ciliary lining of Fallopian tubes thereby reducing the chances of implantation of fertilized egg.  

Methods: This study is aimed at evaluation of subjective and objective stastical benefits and side effects in treatment of DUB in perimenopausal age group with ORM and commonly used 19 nortestosterone compound (progesterone); Norethisterone (NET).

Results: Primary outcome were analyzed at the end of every 3 months and at the end of one year finally. Secondary outcomes of the study in each arm were also assessed. There was stastically significant increase in Hb and stastically significant decrease in ET. Data analysis was done for variables in each arm by t-test to estimate the mean, median, range P and t value for a conclusion. Differences were taken as significant when P<0.05.

Conclusions: ORM is a safe, cost effective, non-steroidal, non-hormonal drug with convenient dosage and better compliance for medical management of perimenopausal DUB with minimum focal pathology. Side effects observed need more evaluation with larger sample size to be statistically significant.


Keywords


Dysfunctional uterine bleeding, Ormeloxifene (Sevista®), Selective estrogen receptor modulator

Full Text:

PDF

References


Boshier and Liggins, 1974: Proceedings of the 5th Asia Oceania Congress of Endocrinology, P-18. The Endocrine Society of India, Chandigarh, as quoted by Dewhurst.

Southam AL and Richart RL. Prognosis for adolescents with menstrual abnormalities, Am J of Obstet and Gynec. 1966;94:637.

Chandra BS, Kumar SS, Shankar BT, Chandra RG, Chandra RA, Prasad KS. Ormeloxifene A Selective Estrogen Receptor Modulator, for the treatment of Dysfunctional Uterine Bleeding. J Obstet Gynaecol, Ind. 2004:56-9.

Brenner PF. Proceedings of symposium: ‘Women with bleeding disorders and role of obstetrician and gynaecologists’.43rd Annual meeting ACOG, AJOG1996;175:761-2.

Shaw RW. Assessment of medical management of menorrhagia. BJOG.1994;101:15-8.

Mishell DR Jr. Non Contraceptive health benefits of oral steroidal contraceptives. AJOG. 1971;110:713-20.

Albright AD, Weeks SR, Duffy MJ. Abnormal uterine bleeding: diagnosis and medical management. Prog Obstet Gynaecol. 1953;12:309-26.

Enmark E, Gustafsson JA. Estrogen receptors an overview. J Intern Med. 1999;246:136-8.

Riggs BL, Hartmann LC. SERMs: Mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-29.

Baker VL, Leitman D, Jaffe RB. SERMs in reproductive medicine and biology. Obstet Gynecol Surv. 2000;55:521-47.

Dutertre M,Smith CL. Molecular mechanisms of SERMs action, J Pharmacol Exp Ther 2000;295:431-7.

Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on lipid profile compared to low dose HRT. J Clin Endocrinol metab 2001;86:755-60.

Osborne CK, ZhaoH, Fuqua SA. SERMs: structure, function and clinical use. Clin Oncol. 2000;18:3172-86.

Yaffe K. Estrogens SERMs and dementia: What is the evidence? Ann NY Acad Sci. 2001;949:215-22.

Jordan VC. Antiestrogens and SERM as multifunctional medicines. Clinical considerations and new agents. J Med Chem. 2003;46:1081-111.

Katzenellenbogen BS, Sun J, Harrington WR, Kraichely DM, Ganessunker D, Katzenellenbogen JA, et al. Structure-function relationships in estrogen receptors and characterization of novel SERMs with unique pharmacological profiles. Ann NY Acad Sci. 2001; 949:6-15.

Shia Shalen, Rumack CM, Wilson SR, Charboneau JW. The uterus and adnexa. In–Diagnostic Ultrasound 2nd ed, New York, 1998;1:519-73.